Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The evaluated claim is directly supported by the provided FDA label excerpt in Section 5.12, stating that prescribing TYGACIL without a proven or strongly suspected bacterial infection is unlikely to provide benefit and increases the risk of developing drug-resistant bacteria.
Category Scores
Accurate Statements
Prescribing TYGACIL in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit and increases the risk of developing drug-resistant bacteria.
Label excerpt, Section 5.12 Development of Drug-Resistant Bacteria: states prescribing TYGACIL in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit and increases the risk of development of drug-resistant bacteria.
Unsupported Statements
The current rate of tigecycline-resistant anaerobes is increasing.
No such resistance-rate trend statement is present in the provided FDA label excerpt.
Tigecycline resistance among anaerobes was present in 22.1% of patients with bacteriologically confirmed anaerobic infections worldwide.
No such specific percentage (22.1%) is present in the provided FDA label excerpt.
Tigecycline resistance among Clostridioides difficile (C. difficile) was higher in the United States (14.5%) compared to other countries (6.5%).
No such specific country/percent breakdown (14.5% vs 6.5%) is present in the provided FDA label excerpt.
Overuse and misuse of tigecycline have accelerated the development of resistance among anaerobes.
No such attribution of cause (overuse/misuse accelerating resistance) is present in the provided FDA label excerpt.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The only evaluated, label-matching claim is a warning-consistent statement discouraging use without a proven or strongly suspected bacterial infection.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Other resistance-statistics claims were not supported by the provided label excerpt (only Section 5.12 was provided).
Suggested Improvement
Limit assertions to the specific on-label language from Section 5.12 (and provide the corresponding label sections if quoting resistance rates by region or organism).